OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels in Metastatic Prostate Cancer Patients; Low Levels Correlate with Improved Survival in Those at Increased Risk for Poor Outcomes
September 28, 2015 at 04:05 AM EDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today results from additional exploratory analyses of the Phase 3 SYNERGY trial ...
